Boston Scientific Corp: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Jul 30, 2019 and accepted by EDGAR at Jul 30, 2019, 20:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $2.63bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $5.12bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $758.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $1.49bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $1.87bn | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $3.64bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2019-04-01 to 2019-06-30 | $968.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2019-01-01 to 2019-06-30 | $1.84bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | $384.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | $925.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $89.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $198.0m | us-gaap:InterestExpense |
| Income tax | 3 months2019-04-01 to 2019-06-30 | −$9.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | $24.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | $154.0m | us-gaap:ProfitLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | $578.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | $0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | $0.41 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | $0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | $0.42 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 1,408,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-01-01 to 2019-06-30 | 1,408,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | $642.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $154.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $123.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $6.33bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $24.31bn | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $4.85bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2019-06-30 | $1.95bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2019-06-30 | $9.43bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0000885725-19-000040. Last ingested by Listed: Nov 6, 2026, 17:38 ET. Listed shows no prices and gives no investment advice.